{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Welcome to the Arena from ICR – Conversations with Today's Innovators & Business Leaders","title":"Lance Baldo MD, CEO, Beacon Therapeutics — Second Sight: A new gene therapy could help restore vision in patients with a rare and devastating ocular disorder","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/821740a1\"></iframe>","width":"100%","height":180,"duration":1767,"description":" Globally, there are hundreds of thousands of people living with X-linked retinitis pigmentosa, a devastating condition that often leads to vision loss in young people. But a new treatment is giving these patients new hope, and creating a tremendous growth opportunity for the company behind it. \n\nOur guest today is Lance Baldo MD, who has served as the CEO of Beacon Therapeutics since July of 2024. Before Beacon, Lance was chief medical officer at Freenome, where he led medical strategy from clinical trials through registration and commercialization, and Chief Medical Officer at Adaptive Biotechnologies, where he was part of the senior leadership team as it transitioned from a private to a publicly held company. \n\nLance is also a medical doctor by training, holding an MD from the University of Connecticut School of Medicine, and a BA in biology from Johns Hopkins University. \n\nToday, he joins us to discuss the extremely exciting results of Beacon’s recent medical trials, how they're navigating the regulatory process on the way to launch, and how their novel gene therapy could help patients with a broad array of ocular diseases. \n\n\nHighlights:\nHow Lance Landed the CEO Job (2:29)\nGene Therapy for the Eye (3:49)\nWho Is Affected by XLRP (4:51)\nA New Hope for Vision Loss (5:38)\nThe Day the Trial Results Came In (9:07)\nWhy It Took a Decade to Get Here (11:50)\nReaction From the Scientific Community (13:35)\nWorking With Regulators (15:20)\nGetting Ready to Launch (18:04)\nTreating Other Ocular Disorders (20:15)\nRaising Money as a CEO (21:26)\nPriorities for 2027 (26:04)\n\n\nFeedback:\n\n\nIf you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, joe@lowerstreet.co","thumbnail_url":"https://img.transistorcdn.com/VPbFZOgoHk78hrWlplrfMSrQROUNxI8jcZ2Gv-hyKm4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mYmFh/NWFlNGJjY2Y0NGFk/YmM2NWJiMTI4NmVh/OWQ4Yi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}